0
2022
Cancer Stem Cells Market

Cancer Stem Cells Market

by Cancer Forms (Breast, Blood, Lung, Brain, Colorectal, Pancreatic, Bladder, Liver, Others), by Application (Trageted Cancerous Stem Cells, Stem Cell-based cancer Therapy): Global Opportunity Analysis and Industry Forecast, 2021-2031

Report Code: A08105
Sep 2022 | Pages: 200
Tables: 128
Charts: 67
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Cancer Stem Cells Market Research, 2031

The global cancer stem cells market size was $1.1 billion in 2021 and is projected to reach $2.7 billion by 2031, growing at a CAGR of 10% from 2022 to 2031. Cancer stem cells (CSCs) are small subpopulations of cells that are capable of self-renewal, differentiation, and tumorigenicity, as well as they, give rise to every type of cell seen in a specific cancer sample.  

The COVID-19 pandemic has had a positive impact on the cancer stem cell industry. One of the most significant advancements in stem cell research during COVID-19 has been the development of genetic engineering which alter the DNA of human and organoid technology in which the three-dimensional structure of the tissue is produced from originated stem cell.

Cancer Stem Cells Market, Cancer Stem Cells Market size, Cancer Stem Cells Market share, Cancer Stem Cells Market trends, Cancer Stem Cells Market growth, Cancer Stem Cells Market analysis, Cancer Stem Cells Market forecast, Cancer Stem Cells Market opportunity

Cancer stem cells are unique in that they can differentiate into several lineages and have the potential to multiply greatly, among other things. The majority of tissues, including the brain, prostate, lungs, and other tissues, include these cells. Cancer therapy benefits greatly from the use of cancer stem cells. It's critical to comprehend the numerous relationships between stem cells and cancer. For instance, stem cell technology focuses on fighting cancer-causing disorders while also providing vital information regarding the cause of the disease.

Major factors driving cancer stem cells market include an increase in R&D activities that facilitates the development of medications to treat cancer, which is the leading cause of death globally. Additionally, the need for a safe and efficient treatment that will completely destroy cancer cells in the body while reducing the patient's risk of relapse or metastasis has increased due to the rising incidence of cancer worldwide. As a result, funding for new treatment technology and cancer-related research studies is increasing rapidly. These factors are anticipated to fuel the cancer stem cell market growth in the forecasted time period.

The clinical procedures involved in stem cell transplantation are critical and involve high risk, such as the radiation therapy that is used to diagnose different types of cancer. For instance, when aggressive tumors are treated with very high doses of radiation therapy, the blood-forming and leukocyte cells are either completely or partially destroyed. In such cases, the patients require an infusion of hematopoietic stem cell transplant, either allogeneic or autologous. Such medical procedures are very costly due to which the middle-class and lower-class sectors have less awareness and access to such therapies. These factors are anticipated to hamper the growth of the cancer stem cell market in forecast time period.

According to the estimates provided by the World Health Organization (WHO), cancer accounted for about 10 million deaths in 2020, making it one of the top causes of mortality. The demand for efficient medicines and transplantation caused by the rise in cancer types like lymphoma, leukemia, osteopetrosis, and other diseases is leading to extensive research in the cancer stem cells. The market for cancer stem cells is expanding as a result of growing investment possibilities provided by the government, top biomedical businesses, and clinical R&D activities conducted globally. Leading pharmaceutical and biomedical businesses are working on innovating new cancer therapy for the treatment of cancer using cancer stem cell. Stem cell-based technology can provide several opportunities in field of cancer therapy. Stem cells can reach solid tumors and micro metastatic lesions to administer anti-tumor agents. In order to avoid the short half-lives of standard antitumor medicines, stem cells can be engineered to express a variety of antitumor agents. The mechanism of stem cells may enhance stem cell-based regeneration medicine as well as anticancer methods that will ultimately play important role in the widespread clinical use of stem cells therapy.

The industry players are investing a lot of efforts in the research and development of smart and unique strategies to sustain their growth in the market. These strategies include product launches, mergers & acquisitions, collaborations, partnerships, and refurbishing of existing technology. On June 8, 2022, BlueRock Therapeutics LP, a biopharmaceutical firm and wholly-owned subsidiary of Bayer AG, announced the establishment of a new cell treatment innovation site on Bayer's campus in Berlin, Germany. While working independently, the BlueRock team will take advantage of the knowledge held by multiple Bayer departments in order to expand and expedite the company's clinical studies to Europe.

The key players profiled in this report include AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A.

The global cancer stem cells market is segmented on the basis of cancer forms, application, and region. By cancer forms, the market is sub-segmented into breast, blood, lung, brain, colorectal, pancreatic, bladder, liver, and others. By application, the market is classified into targeted cancerous stem cells, stem cell-based cancer therapy. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The cancer stem cells market is segmented into Cancer Forms and Application.

Cancer Stem Cells Market

By cancer forms, the breast cancer sub-segment dominated the cancer stem cells market in 2021. Breast cancer is one of the most common diseases affecting women globally. The established risk factors for breast cancer include advancing age, reproductive variables, mammographic density, and genetic factors and family history. Numerous other elements, including dietary fat intake, alcohol consumption, exposure to solvents, and pesticides, have also been suggested as potential risk elements for breast cancer among females. The incidence of breast cancer is steadily rising in most industrialized nations and in communities that have recently undergone or are undergoing westernization such as change in lifestyles, pollution, change in diet and physical activity patterns. These are predicted to be the major factors affecting the cancer stem cells market size during the forecast period.

By cancer forms, the bladder cancer sub-segment shows the fastest growth in the cancer stem cells market in 2021. The ninth most common disease in the world is the bladder cancer. The bladder cancer is a malignant development of aberrant cells. Inhaling carcinogens from the environment, including cigarette smoke, volatile coal tar compounds, cooking hood smoke, and diesel exhaust can lead to bladder cancer. The main known cause of bladder cancer in the majority of population is smoking. About half of bladder cancer cases are caused by smoking. Smoking cessation was linked to a lower risk of bladder cancer, just like it was for many other malignancies caused by smoking. These factors are anticipated to fuel the growth of cancer cell stems market for bladder cancer during the forecast period time.

Cancer Stem Cells Market

By application, the stem cell-based cancer therapy sub-segment dominated the global cancer stem cells market share in 2021. Traditional surgical or chemo radiotherapeutic methods typically cannot eradicate metastatic cancer cells, and disease recurrence is very common in such cases, after the treatment. On the other hand, stem cell-based therapies are becoming more and more promising for the treatment of cancer. By focusing on both metastatic tumor foci and primary stem cells, novel delivery strategies can be developed. In preclinical animal models, stem cells modified to persistently express different cytotoxic drugs reduce tumor sizes and lengthen longevity have shown positive results. Additionally, they have been used as viral and nanoparticle carriers to improve primary therapeutic efficacies and lessen side effects of treatment. Additionally, stem cells can be used in cancer stem cell-targeted therapy, immunotherapy, and applications for anticancer drug screening.

Cancer Stem Cells Market

By region, North America dominated the global cancer market size in 2021 and is projected to remain the fastest-growing sub-segment during the forecast period. North America has well-established healthcare and medical research facilities. The United States is one of the top locations for cutting-edge research and development in cancer stem cells and has a sizably large budget. The existence of numerous renowned biomedical research institutions and their active involvement in the development of novel therapies and transplants are projected to support the market's expected revenue growth in this area. The availability of cutting-edge research infrastructure, the involvement of numerous important medical institutes, the rise in research and development initiatives to create therapeutic options for chronic diseases, and the ease with which clinical trial approval can be granted are all expected to contribute to market growth.

COVID-19 Impact on Cancer Stem Cells Industry

  • The COVID-19 pandemic had a positive impact on the cancer stem cells industry. One of the most significant advancements in stem cell research during COVID-19 has been the development of genetic engineering which alter the DNA of human and organoid technology in which the three-dimensional structure of the tissue is produced from originated stem cell.
  • Experimental research is essential to providing cancer patients with the best care possible, many centers are working to modify their plans and adjust to the new environment without pausing their current work
  • The adoption of hematopoietic cell transplantation (HCT) and allogeneic stem cell therapy has grown in cancer patients who have COVID-19 infections.
  • During COVID-19, one of the most significant advancements in stem cell research was genetic engineering and organoid technology.

Key Benefits For Stakeholders

  • The report provides exclusive and comprehensive analysis of the global cancer stem cells market trends along with the cancer stem cells market forecast.
  • The report elucidates the cancer stem cells market opportunity along with key drivers, and restraints of the market. It is a compilation of detailed information, inputs from industry participants and industry experts across the value chain, and quantitative and qualitative assessment by industry analysts.
  • Porter’s five forces analysis helps analyse the potential of the buyers & suppliers and the competitive scenario of the market for strategy building.
  • The report entailing the cancer stem cells market analysis maps the qualitative sway of various industry factors on market segments as well as geographies.
  • The data in this report aims on market dynamics, trends, and developments affecting the cancer stem cells market growth.

    Cancer Stem Cells Market Report Highlights

    Aspects Details
    By Cancer Forms
    • Breast
    • Blood
    • Lung
    • Brain
    • Colorectal
    • Pancreatic
    • Bladder
    • Liver
    • Others
    By Application
    • Trageted Cancerous Stem Cells
    • Stem Cell-based cancer Therapy
    By Region
    • North America  (U.S., Canada, Mexico)
    • Europe  (Germany, United Kingdom, France, Spain, Italy, Rest of Europe)
    • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest Of Asia Pacific)
    • LAMEA  (Brazil, Saudi Arabia, UAE, South Africa, Rest of LAMEA)
    Key Market Players AbbVie Inc., STEMCELL Technologies Inc., Bionomics, Thermo Fisher Scientific Inc., Miltenyi Biotec, Merck KGaA, MacroGenics, Inc., Lineage Cell Therapeutics, Inc., FUJIFILM Irvine Scientific., Stemline Therapeutics, Inc.
     
    • CHAPTER 1:INTRODUCTION

      • 1.1.Report description

      • 1.2.Key market segments

      • 1.3.Key benefits to the stakeholders

      • 1.4.Research Methodology

        • 1.4.1.Secondary research

        • 1.4.2.Primary research

        • 1.4.3.Analyst tools and models

    • CHAPTER 2:EXECUTIVE SUMMARY

      • 2.1.Key findings of the study

      • 2.2.CXO Perspective

    • CHAPTER 3:MARKET OVERVIEW

      • 3.1.Market definition and scope

      • 3.2.Key findings

        • 3.2.1.Top investment pockets

      • 3.3.Porter’s five forces analysis

      • 3.4.Top player positioning

      • 3.5.Market dynamics

        • 3.5.1.Drivers

        • 3.5.2.Restraints

        • 3.5.3.Opportunities

      • 3.6.COVID-19 Impact Analysis on the market

      • 3.7.Regulatory Guidelines

      • 3.8.Value Chain Analysis

      • 3.9.Market Share Analysis

      • 3.10.Key Regulation Analysis

      • 3.11.Patent Landscape

    • CHAPTER 4: CANCER STEM CELLS MARKET, BY CANCER FORMS

      • 4.1 Overview

        • 4.1.1 Market size and forecast

      • 4.2 Breast

        • 4.2.1 Key market trends, growth factors and opportunities

        • 4.2.2 Market size and forecast, by region

        • 4.2.3 Market analysis by country

      • 4.3 Blood

        • 4.3.1 Key market trends, growth factors and opportunities

        • 4.3.2 Market size and forecast, by region

        • 4.3.3 Market analysis by country

      • 4.4 Lung

        • 4.4.1 Key market trends, growth factors and opportunities

        • 4.4.2 Market size and forecast, by region

        • 4.4.3 Market analysis by country

      • 4.5 Brain

        • 4.5.1 Key market trends, growth factors and opportunities

        • 4.5.2 Market size and forecast, by region

        • 4.5.3 Market analysis by country

      • 4.6 Colorectal

        • 4.6.1 Key market trends, growth factors and opportunities

        • 4.6.2 Market size and forecast, by region

        • 4.6.3 Market analysis by country

      • 4.7 Pancreatic

        • 4.7.1 Key market trends, growth factors and opportunities

        • 4.7.2 Market size and forecast, by region

        • 4.7.3 Market analysis by country

      • 4.8 Bladder

        • 4.8.1 Key market trends, growth factors and opportunities

        • 4.8.2 Market size and forecast, by region

        • 4.8.3 Market analysis by country

      • 4.9 Liver

        • 4.9.1 Key market trends, growth factors and opportunities

        • 4.9.2 Market size and forecast, by region

        • 4.9.3 Market analysis by country

      • 5.0 Others

        • 5.0.1 Key market trends, growth factors and opportunities

        • 5.0.2 Market size and forecast, by region

        • 5.0.3 Market analysis by country

    • CHAPTER 5: CANCER STEM CELLS MARKET, BY APPLICATION

      • 5.1 Overview

        • 5.1.1 Market size and forecast

      • 5.2 Trageted Cancerous Stem Cells

        • 5.2.1 Key market trends, growth factors and opportunities

        • 5.2.2 Market size and forecast, by region

        • 5.2.3 Market analysis by country

      • 5.3 Stem Cell-based cancer Therapy

        • 5.3.1 Key market trends, growth factors and opportunities

        • 5.3.2 Market size and forecast, by region

        • 5.3.3 Market analysis by country

    • CHAPTER 6: CANCER STEM CELLS MARKET, BY REGION

      • 6.1 Overview

        • 6.1.1 Market size and forecast

      • 6.2 North America

        • 6.2.1 Key trends and opportunities

        • 6.2.2 North America Market size and forecast, by Cancer Forms

        • 6.2.3 North America Market size and forecast, by Application

        • 6.2.4 North America Market size and forecast, by country

          • 6.2.4.1 U.S.
            • 6.2.4.1.1 Market size and forecast, by Cancer Forms
            • 6.2.4.1.2 Market size and forecast, by Application
          • 6.2.4.2 Canada
            • 6.2.4.2.1 Market size and forecast, by Cancer Forms
            • 6.2.4.2.2 Market size and forecast, by Application
          • 6.2.4.3 Mexico
            • 6.2.4.3.1 Market size and forecast, by Cancer Forms
            • 6.2.4.3.2 Market size and forecast, by Application
      • 6.3 Europe

        • 6.3.1 Key trends and opportunities

        • 6.3.2 Europe Market size and forecast, by Cancer Forms

        • 6.3.3 Europe Market size and forecast, by Application

        • 6.3.4 Europe Market size and forecast, by country

          • 6.3.4.1 Germany
            • 6.3.4.1.1 Market size and forecast, by Cancer Forms
            • 6.3.4.1.2 Market size and forecast, by Application
          • 6.3.4.2 United Kingdom
            • 6.3.4.2.1 Market size and forecast, by Cancer Forms
            • 6.3.4.2.2 Market size and forecast, by Application
          • 6.3.4.3 France
            • 6.3.4.3.1 Market size and forecast, by Cancer Forms
            • 6.3.4.3.2 Market size and forecast, by Application
          • 6.3.4.4 Spain
            • 6.3.4.4.1 Market size and forecast, by Cancer Forms
            • 6.3.4.4.2 Market size and forecast, by Application
          • 6.3.4.5 Italy
            • 6.3.4.5.1 Market size and forecast, by Cancer Forms
            • 6.3.4.5.2 Market size and forecast, by Application
          • 6.3.4.6 Rest of Europe
            • 6.3.4.6.1 Market size and forecast, by Cancer Forms
            • 6.3.4.6.2 Market size and forecast, by Application
      • 6.4 Asia-Pacific

        • 6.4.1 Key trends and opportunities

        • 6.4.2 Asia-Pacific Market size and forecast, by Cancer Forms

        • 6.4.3 Asia-Pacific Market size and forecast, by Application

        • 6.4.4 Asia-Pacific Market size and forecast, by country

          • 6.4.4.1 China
            • 6.4.4.1.1 Market size and forecast, by Cancer Forms
            • 6.4.4.1.2 Market size and forecast, by Application
          • 6.4.4.2 Japan
            • 6.4.4.2.1 Market size and forecast, by Cancer Forms
            • 6.4.4.2.2 Market size and forecast, by Application
          • 6.4.4.3 India
            • 6.4.4.3.1 Market size and forecast, by Cancer Forms
            • 6.4.4.3.2 Market size and forecast, by Application
          • 6.4.4.4 South Korea
            • 6.4.4.4.1 Market size and forecast, by Cancer Forms
            • 6.4.4.4.2 Market size and forecast, by Application
          • 6.4.4.5 Australia
            • 6.4.4.5.1 Market size and forecast, by Cancer Forms
            • 6.4.4.5.2 Market size and forecast, by Application
          • 6.4.4.6 Rest Of Asia Pacific
            • 6.4.4.6.1 Market size and forecast, by Cancer Forms
            • 6.4.4.6.2 Market size and forecast, by Application
      • 6.5 LAMEA

        • 6.5.1 Key trends and opportunities

        • 6.5.2 LAMEA Market size and forecast, by Cancer Forms

        • 6.5.3 LAMEA Market size and forecast, by Application

        • 6.5.4 LAMEA Market size and forecast, by country

          • 6.5.4.1 Brazil
            • 6.5.4.1.1 Market size and forecast, by Cancer Forms
            • 6.5.4.1.2 Market size and forecast, by Application
          • 6.5.4.2 Saudi Arabia
            • 6.5.4.2.1 Market size and forecast, by Cancer Forms
            • 6.5.4.2.2 Market size and forecast, by Application
          • 6.5.4.3 UAE
            • 6.5.4.3.1 Market size and forecast, by Cancer Forms
            • 6.5.4.3.2 Market size and forecast, by Application
          • 6.5.4.4 South Africa
            • 6.5.4.4.1 Market size and forecast, by Cancer Forms
            • 6.5.4.4.2 Market size and forecast, by Application
          • 6.5.4.5 Rest of LAMEA
            • 6.5.4.5.1 Market size and forecast, by Cancer Forms
            • 6.5.4.5.2 Market size and forecast, by Application
    • CHAPTER 7: COMPANY LANDSCAPE

      • 7.1. Introduction

      • 7.2. Top winning strategies

      • 7.3. Product Mapping of Top 10 Player

      • 7.4. Competitive Dashboard

      • 7.5. Competitive Heatmap

      • 7.6. Key developments

    • CHAPTER 8: COMPANY PROFILES

      • 8.1 Thermo Fisher Scientific Inc.

        • 8.1.1 Company overview

        • 8.1.2 Company snapshot

        • 8.1.3 Operating business segments

        • 8.1.4 Product portfolio

        • 8.1.5 Business performance

        • 8.1.6 Key strategic moves and developments

      • 8.2 AbbVie Inc.

        • 8.2.1 Company overview

        • 8.2.2 Company snapshot

        • 8.2.3 Operating business segments

        • 8.2.4 Product portfolio

        • 8.2.5 Business performance

        • 8.2.6 Key strategic moves and developments

      • 8.3 Miltenyi Biotec

        • 8.3.1 Company overview

        • 8.3.2 Company snapshot

        • 8.3.3 Operating business segments

        • 8.3.4 Product portfolio

        • 8.3.5 Business performance

        • 8.3.6 Key strategic moves and developments

      • 8.4 STEMCELL Technologies Inc.

        • 8.4.1 Company overview

        • 8.4.2 Company snapshot

        • 8.4.3 Operating business segments

        • 8.4.4 Product portfolio

        • 8.4.5 Business performance

        • 8.4.6 Key strategic moves and developments

      • 8.5 Merck KGaA

        • 8.5.1 Company overview

        • 8.5.2 Company snapshot

        • 8.5.3 Operating business segments

        • 8.5.4 Product portfolio

        • 8.5.5 Business performance

        • 8.5.6 Key strategic moves and developments

      • 8.6 Stemline Therapeutics, Inc.

        • 8.6.1 Company overview

        • 8.6.2 Company snapshot

        • 8.6.3 Operating business segments

        • 8.6.4 Product portfolio

        • 8.6.5 Business performance

        • 8.6.6 Key strategic moves and developments

      • 8.7 MacroGenics, Inc.

        • 8.7.1 Company overview

        • 8.7.2 Company snapshot

        • 8.7.3 Operating business segments

        • 8.7.4 Product portfolio

        • 8.7.5 Business performance

        • 8.7.6 Key strategic moves and developments

      • 8.8 Bionomics

        • 8.8.1 Company overview

        • 8.8.2 Company snapshot

        • 8.8.3 Operating business segments

        • 8.8.4 Product portfolio

        • 8.8.5 Business performance

        • 8.8.6 Key strategic moves and developments

      • 8.9 FUJIFILM Irvine Scientific.

        • 8.9.1 Company overview

        • 8.9.2 Company snapshot

        • 8.9.3 Operating business segments

        • 8.9.4 Product portfolio

        • 8.9.5 Business performance

        • 8.9.6 Key strategic moves and developments

      • 8.10 Lineage Cell Therapeutics, Inc.

        • 8.10.1 Company overview

        • 8.10.2 Company snapshot

        • 8.10.3 Operating business segments

        • 8.10.4 Product portfolio

        • 8.10.5 Business performance

        • 8.10.6 Key strategic moves and developments

    • LIST OF TABLES

    • TABLE 1. GLOBAL CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 2. CANCER STEM CELLS MARKET SIZE, FOR BREAST, BY REGION, 2021-2031 ($MILLION)
      TABLE 3. CANCER STEM CELLS MARKET FOR BREAST, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 4. CANCER STEM CELLS MARKET SIZE, FOR BLOOD, BY REGION, 2021-2031 ($MILLION)
      TABLE 5. CANCER STEM CELLS MARKET FOR BLOOD, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 6. CANCER STEM CELLS MARKET SIZE, FOR LUNG, BY REGION, 2021-2031 ($MILLION)
      TABLE 7. CANCER STEM CELLS MARKET FOR LUNG, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 8. CANCER STEM CELLS MARKET SIZE, FOR BRAIN, BY REGION, 2021-2031 ($MILLION)
      TABLE 9. CANCER STEM CELLS MARKET FOR BRAIN, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 10. CANCER STEM CELLS MARKET SIZE, FOR COLORECTAL, BY REGION, 2021-2031 ($MILLION)
      TABLE 11. CANCER STEM CELLS MARKET FOR COLORECTAL, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 12. CANCER STEM CELLS MARKET SIZE, FOR PANCREATIC, BY REGION, 2021-2031 ($MILLION)
      TABLE 13. CANCER STEM CELLS MARKET FOR PANCREATIC, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 14. CANCER STEM CELLS MARKET SIZE, FOR BLADDER, BY REGION, 2021-2031 ($MILLION)
      TABLE 15. CANCER STEM CELLS MARKET FOR BLADDER, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 16. CANCER STEM CELLS MARKET SIZE, FOR LIVER, BY REGION, 2021-2031 ($MILLION)
      TABLE 17. CANCER STEM CELLS MARKET FOR LIVER, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 18. CANCER STEM CELLS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
      TABLE 19. CANCER STEM CELLS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 20. GLOBAL CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 21. CANCER STEM CELLS MARKET SIZE, FOR TRAGETED CANCEROUS STEM CELLS, BY REGION, 2021-2031 ($MILLION)
      TABLE 22. CANCER STEM CELLS MARKET FOR TRAGETED CANCEROUS STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 23. CANCER STEM CELLS MARKET SIZE, FOR STEM CELL-BASED CANCER THERAPY, BY REGION, 2021-2031 ($MILLION)
      TABLE 24. CANCER STEM CELLS MARKET FOR STEM CELL-BASED CANCER THERAPY, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 25. CANCER STEM CELLS MARKET, BY REGION, 2021-2031 ($MILLION)
      TABLE 26. NORTH AMERICA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 27. NORTH AMERICA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 28. NORTH AMERICA CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 29. U.S. CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 30. U.S. CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 31. CANADA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 32. CANADA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 33. MEXICO CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 34. MEXICO CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 35. EUROPE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 36. EUROPE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 37. EUROPE CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 38. GERMANY CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 39. GERMANY CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 40. UNITED KINGDOM CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 41. UNITED KINGDOM CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 42. FRANCE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 43. FRANCE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 44. SPAIN CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 45. SPAIN CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 46. ITALY CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 47. ITALY CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 48. REST OF EUROPE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 49. REST OF EUROPE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 50. ASIA-PACIFIC CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 51. ASIA-PACIFIC CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 52. ASIA-PACIFIC CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 53. CHINA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 54. CHINA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 55. JAPAN CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 56. JAPAN CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 57. INDIA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 58. INDIA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 59. SOUTH KOREA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 60. SOUTH KOREA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 61. AUSTRALIA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 62. AUSTRALIA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 63. REST OF ASIA PACIFIC CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 64. REST OF ASIA PACIFIC CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 65. LAMEA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 66. LAMEA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 67. LAMEA CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
      TABLE 68. BRAZIL CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 69. BRAZIL CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 70. SAUDI ARABIA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 71. SAUDI ARABIA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 72. UAE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 73. UAE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 74. SOUTH AFRICA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 75. SOUTH AFRICA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 76. REST OF LAMEA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
      TABLE 77. REST OF LAMEA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
      TABLE 78.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
      TABLE 79.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
      TABLE 80.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
      TABLE 81.THERMO FISHER SCIENTIFIC INC.: NET SALES,
      TABLE 82.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
      TABLE 83.ABBVIE INC.: COMPANY SNAPSHOT
      TABLE 84.ABBVIE INC.: OPERATING SEGMENTS
      TABLE 85.ABBVIE INC.: PRODUCT PORTFOLIO
      TABLE 86.ABBVIE INC.: NET SALES,
      TABLE 87.ABBVIE INC.: KEY STRATERGIES
      TABLE 88.MILTENYI BIOTEC: COMPANY SNAPSHOT
      TABLE 89.MILTENYI BIOTEC: OPERATING SEGMENTS
      TABLE 90.MILTENYI BIOTEC: PRODUCT PORTFOLIO
      TABLE 91.MILTENYI BIOTEC: NET SALES,
      TABLE 92.MILTENYI BIOTEC: KEY STRATERGIES
      TABLE 93.STEMCELL TECHNOLOGIES INC.: COMPANY SNAPSHOT
      TABLE 94.STEMCELL TECHNOLOGIES INC.: OPERATING SEGMENTS
      TABLE 95.STEMCELL TECHNOLOGIES INC.: PRODUCT PORTFOLIO
      TABLE 96.STEMCELL TECHNOLOGIES INC.: NET SALES,
      TABLE 97.STEMCELL TECHNOLOGIES INC.: KEY STRATERGIES
      TABLE 98.MERCK KGAA: COMPANY SNAPSHOT
      TABLE 99.MERCK KGAA: OPERATING SEGMENTS
      TABLE 100.MERCK KGAA: PRODUCT PORTFOLIO
      TABLE 101.MERCK KGAA: NET SALES,
      TABLE 102.MERCK KGAA: KEY STRATERGIES
      TABLE 103.STEMLINE THERAPEUTICS, INC.: COMPANY SNAPSHOT
      TABLE 104.STEMLINE THERAPEUTICS, INC.: OPERATING SEGMENTS
      TABLE 105.STEMLINE THERAPEUTICS, INC.: PRODUCT PORTFOLIO
      TABLE 106.STEMLINE THERAPEUTICS, INC.: NET SALES,
      TABLE 107.STEMLINE THERAPEUTICS, INC.: KEY STRATERGIES
      TABLE 108.MACROGENICS, INC.: COMPANY SNAPSHOT
      TABLE 109.MACROGENICS, INC.: OPERATING SEGMENTS
      TABLE 110.MACROGENICS, INC.: PRODUCT PORTFOLIO
      TABLE 111.MACROGENICS, INC.: NET SALES,
      TABLE 112.MACROGENICS, INC.: KEY STRATERGIES
      TABLE 113.BIONOMICS: COMPANY SNAPSHOT
      TABLE 114.BIONOMICS: OPERATING SEGMENTS
      TABLE 115.BIONOMICS: PRODUCT PORTFOLIO
      TABLE 116.BIONOMICS: NET SALES,
      TABLE 117.BIONOMICS: KEY STRATERGIES
      TABLE 118.FUJIFILM IRVINE SCIENTIFIC.: COMPANY SNAPSHOT
      TABLE 119.FUJIFILM IRVINE SCIENTIFIC.: OPERATING SEGMENTS
      TABLE 120.FUJIFILM IRVINE SCIENTIFIC.: PRODUCT PORTFOLIO
      TABLE 121.FUJIFILM IRVINE SCIENTIFIC.: NET SALES,
      TABLE 122.FUJIFILM IRVINE SCIENTIFIC.: KEY STRATERGIES
      TABLE 123.LINEAGE CELL THERAPEUTICS, INC.: COMPANY SNAPSHOT
      TABLE 124.LINEAGE CELL THERAPEUTICS, INC.: OPERATING SEGMENTS
      TABLE 125.LINEAGE CELL THERAPEUTICS, INC.: PRODUCT PORTFOLIO
      TABLE 126.LINEAGE CELL THERAPEUTICS, INC.: NET SALES,
      TABLE 127.LINEAGE CELL THERAPEUTICS, INC.: KEY STRATERGIES
    • LIST OF FIGURES

    • FIGURE 1.CANCER STEM CELLS MARKET SEGMENTATION
      FIGURE 2.CANCER STEM CELLS MARKET,2021-2031
      FIGURE 3.CANCER STEM CELLS MARKET,2021-2031
      FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
      FIGURE 5.PORTER FIVE-1
      FIGURE 6.PORTER FIVE-2
      FIGURE 7.PORTER FIVE-3
      FIGURE 8.PORTER FIVE-4
      FIGURE 9.PORTER FIVE-5
      FIGURE 10.TOP PLAYER POSITIONING
      FIGURE 11.CANCER STEM CELLS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
      FIGURE 12.REGULATORY GUIDELINES
      FIGURE 13.VALUE CHAIN ANALYSIS
      FIGURE 14.MARKET SHARE ANALYSIS
      FIGURE 15.KEY REGULATION ANALYSIS
      FIGURE 16.PATENT ANALYSIS BY COMPANY
      FIGURE 17.PATENT ANALYSIS BY COUNTRY
      FIGURE 18.CANCER STEM CELLS MARKET,BY CANCER FORMS,2021(%)
      FIGURE 19.COMPARATIVE SHARE ANALYSIS OF BREAST CANCER STEM CELLS MARKET,2021-2031(%)
      FIGURE 20.COMPARATIVE SHARE ANALYSIS OF BLOOD CANCER STEM CELLS MARKET,2021-2031(%)
      FIGURE 21.COMPARATIVE SHARE ANALYSIS OF LUNG CANCER STEM CELLS MARKET,2021-2031(%)
      FIGURE 22.COMPARATIVE SHARE ANALYSIS OF BRAIN CANCER STEM CELLS MARKET,2021-2031(%)
      FIGURE 23.COMPARATIVE SHARE ANALYSIS OF COLORECTAL CANCER STEM CELLS MARKET,2021-2031(%)
      FIGURE 24.COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER STEM CELLS MARKET,2021-2031(%)
      FIGURE 25.COMPARATIVE SHARE ANALYSIS OF BLADDER CANCER STEM CELLS MARKET,2021-2031(%)
      FIGURE 26.COMPARATIVE SHARE ANALYSIS OF LIVER CANCER STEM CELLS MARKET,2021-2031(%)
      FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OTHERS CANCER STEM CELLS MARKET,2021-2031(%)
      FIGURE 28.CANCER STEM CELLS MARKET,BY APPLICATION,2021(%)
      FIGURE 29.COMPARATIVE SHARE ANALYSIS OF TRAGETED CANCEROUS STEM CELLS CANCER STEM CELLS MARKET,2021-2031(%)
      FIGURE 30.COMPARATIVE SHARE ANALYSIS OF STEM CELL-BASED CANCER THERAPY CANCER STEM CELLS MARKET,2021-2031(%)
      FIGURE 31.CANCER STEM CELLS MARKET BY REGION,2021
      FIGURE 32.U.S. CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 33.CANADA CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 34.MEXICO CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 35.GERMANY CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 36.UNITED KINGDOM CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 37.FRANCE CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 38.SPAIN CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 39.ITALY CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 40.REST OF EUROPE CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 41.CHINA CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 42.JAPAN CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 43.INDIA CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 44.SOUTH KOREA CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 45.AUSTRALIA CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 46.REST OF ASIA PACIFIC CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 47.BRAZIL CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 48.SAUDI ARABIA CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 49.UAE CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 50.SOUTH AFRICA CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 51.REST OF LAMEA CANCER STEM CELLS MARKET,2021-2031($MILLION)
      FIGURE 52. TOP WINNING STRATEGIES, BY YEAR
      FIGURE 53. TOP WINNING STRATEGIES, BY DEVELOPMENT
      FIGURE 54. TOP WINNING STRATEGIES, BY COMPANY
      FIGURE 55.PRODUCT MAPPING OF TOP 10 PLAYERS
      FIGURE 56.COMPETITIVE DASHBOARD
      FIGURE 57.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
      FIGURE 58.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)
      FIGURE 59.ABBVIE INC..: NET SALES ,($MILLION)
      FIGURE 60.MILTENYI BIOTEC.: NET SALES ,($MILLION)
      FIGURE 61.STEMCELL TECHNOLOGIES INC..: NET SALES ,($MILLION)
      FIGURE 62.MERCK KGAA.: NET SALES ,($MILLION)
      FIGURE 63.STEMLINE THERAPEUTICS, INC..: NET SALES ,($MILLION)
      FIGURE 64.MACROGENICS, INC..: NET SALES ,($MILLION)
      FIGURE 65.BIONOMICS.: NET SALES ,($MILLION)
      FIGURE 66.FUJIFILM IRVINE SCIENTIFIC..: NET SALES ,($MILLION)
      FIGURE 67.LINEAGE CELL THERAPEUTICS, INC..: NET SALES ,($MILLION)

     
     

    Increase in the prevalence rate due to smoking, unhealthy lifestyle, and addiction to alcoholism results in an increase in the patient count of cancerous patients. In addition, as people are becoming aware of cancer, there is a decrease in its mortality rate. Currently, numerous types of cancer are coming across globally and its rate is increasing day by day. Cancer stem cell-based therapies provide better solutions to healthcare professionals for treatment of the cancer patients. However, the high cost of stem cell therapy is not affordable to a middle-class family and complicated clinical procedures are the key factors expected to hamper the market growth during the forecast period. On the contrary, the rapid occurrence of cancer disease and the rise in use of stem cell therapy are factors anticipated to provide remunerative opportunities for key players to maintain the pace of the cancer stem cell market in the upcoming years.

    Among the analyzed regions, North America is expected to account for the highest revenue in the market by the end of 2031, followed by Asia-Pacific, Europe, and LAMEA. Active participation in research and easy approval of clinical trials are the key factors responsible for the leading position of North America in the global cancer stem cell market.

    PURCHASE OPTIONS

    Call or Email us

    U.S.-Canada Toll-free: +1-800-792-5285
    Int'l : +1-503-894-6022
    Europe : +44-845-528-1300
    Email : help@alliedmarketresearch.com
     
    FREQUENTLY ASKED QUESTIONS?

    A. Self-renewal is an important feature of stem cells in normal tissue and malignant tissues. Stem cell transplant is a process that repairs stem cells that help to form blood in persons destroyed due to high dosages of radiation therapy or chemotherapy that are used to treat certain cancers, which is estimated to generate excellent opportunities in the cancer stem cell market

    A. The major growth strategies adopted by cancer stem cell market players are merger & acquisition and advanced product development.

    A. North America will provide more business opportunities for the global cancer stem cell market in the future.

    A. AdnaGen GmbH, Advanced Cell Diagnostics, Inc., and AVIVA Biosciences Corporation are major players in the cancer stem cell market.

    A. The breast cancer sub-segment of the cancer form acquired the maximum share of the global cancer stem cell market in 2021.

    A. The report provides an extensive qualitative and quantitative analysis of the current trends and future estimations of the global cancer stem cell market from 2021 to 2031 to determine the prevailing opportunities.

    A. The use of cancer stem cell in the recurrence of tumors and drug resistance development is estimated to drive the adoption of cancer stem cell.

    A. The rising application of cancer stem cell in the treatment of cancer in therapeutics and medicine is anticipated to boost the cancer stem cell market in the upcoming years.

    Looking for Customization?

     Customization Request

    Have a Question?

     Speak with Analyst

    Any Confusion?

     Inquire Before Buying

    Have a glance of the Report

      Request Sample
    RELATED TAGS

    Purchase Full Report of
    Cancer Stem Cells Market

    Start reading instantly.
    This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

    • Online Only
    • $3,570
    • Online cloud access only
    • Restricted print, copy, paste & download
    • Read only
    • Free industry update
      (Within 180 days)
    • Free report update in next update cycle
      (Sep 2023 - Sep 2024)
    • Data Pack
    • $3,840
    • Restricted to one authorized user
    • One print only
    • Available in
      Excel
    • Free industry update
      (Within 180 days)
    •   Free report update in next update cycle
      (Sep 2023 - Sep 2024)
    • Single User
    • $5,730
    • Restricted to one authorized user
    • One print only
    • Available in
      PDF
    • Free industry update
      (Within 180 days)
    •   Free report update in next update cycle
      (Sep 2023 - Sep 2024)
    • Five Users
    • $6,450
    • Limited to five authorized users
    • Print upto five copies
    • Available in
      PDF
    • Free industry update
      (Within 180 days)
    •   Free report update in next update cycle
      (Sep 2023 - Sep 2024)
    • Enterprise
      License/PDF

    • $9,600
    • Unlimited
      within
      company/enterprise
    • Available in Excel & PDF
    • Free industry update
      (Within 180 days)
    •   Free report update in next update cycle
      (Sep 2023 - Sep 2024)
    • Library
      Membership

    • $999 $ 1,175
      Per User/ Per month/ Billed annually
    • Published Content
      E-access
    • Company Profiles
      E-access
    • Newly Added Content Access
    • 10 PDF
      Downloads
    • 5 Excel Data
      Pack Downloads
    • 250 Company Profiles PDF Downloads
    • Buy Now

    *Taxes/Fees, if applicable will be added during checkout. All prices in USD

    RELATED REPORTS
     

    Why Allied Market Research?

     

    Infallible Methodology

    To ensure high-level data integrity, accurate analysis, and impeccable forecasts

    Analyst Support

    For complete satisfaction

    Customization

    On-demand customization of scope of the report to exactly meet your needs

    TARGETED MARKET VIEW

    Targeted market view to provide pertinent information and save time of readers

    Get fresh content delivered

    Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

    Get Industry Data Alerts

    Why Allied Market Research?

    Infallible Methodology

    To ensure high-level data integrity, accurate analysis, and impeccable forecasts

    Analyst Support

    For complete satisfaction

    Customization

    On-demand customization of scope of the report to exactly meet your needs

    TARGETED MARKET VIEW

    Targeted market view to provide pertinent information and save time of readers